{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:01:25Z","timestamp":1790805685288,"version":"4.1.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bulcan.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:32:56Z","timestamp":1639567976000},"page":"S143-S154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S","title":["DESCAR-T, le registre national des patients trait\u00e9s par CAR-T Cells"],"prefix":"10.1016","volume":"108","author":[{"given":"Florence","family":"Broussais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle Roth","family":"Guepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gandemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Leguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Nguyen Quoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Schwartzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.07.002_bib0040","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T Cells in refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.07.002_bib0045","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2021.07.002_bib0050","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.07.002_bib0055","unstructured":"Avis du 5\u00a0d\u00e9cembre 2018\u00a0de la COMMISSION DE LA TRANSPARENCE concernant YESCARTA\u00ae (indication concern\u00e9e: \u00ab YESCARTA est indiqu\u00e9 pour le traitement des patients adultes atteints de lymphome diffus \u00e0 grandes cellules B (LDGCB) et de lymphome m\u00e9diastinal primitif \u00e0 grandes cellules B.(LMPGCB) r\u00e9fractaire ou en rechute, apr\u00e8s au moins deux lignes de traitement syst\u00e9mique. \u00bb)."},{"key":"10.1016\/j.bulcan.2021.07.002_bib0060","unstructured":"Avis du 12\u00a0d\u00e9cembre 2018\u00a0de la COMMISSION DE LA TRANSPARENCE concernant KYMRIAH\u00ae (indication concern\u00e9e: \u00ab Traitement des adultes atteints de lymphome diffus \u00e0 grandes cellules B.(LDGCB) en rechute ou r\u00e9fractaire apr\u00e8s la deuxi\u00e8me ligne ou plus d\u2019un traitement syst\u00e9mique \u00bb)."},{"key":"10.1016\/j.bulcan.2021.07.002_bib0065","unstructured":"Avis du 12\u00a0d\u00e9cembre 2018\u00a0de la COMMISSION DE LA TRANSPARENCE concernant KYMRIAH\u00ae (indication concern\u00e9e: Traitement des enfants et jeunes adultes jusqu\u2019\u00e0 25\u00a0ans atteints de leuc\u00e9mie aig\u00fce lymphoblastique.(LAL) \u00e0 cellules B r\u00e9fractaire, en rechute apr\u00e8s greffe ou apr\u00e8s la deuxi\u00e8me rechute ou plus. \u00bb)."},{"key":"10.1016\/j.bulcan.2021.07.002_bib0070","article-title":"ATU CAR-T anti-CD19: Aspects organisationnels et donn\u00e9es en vie r\u00e9elle pour les patients trait\u00e9s en France pour un lymphome diffus \u00e0 grandes cellules B r\u00e9fractaire ou en rechute","author":"Thieblemont","year":"2019","journal-title":"Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019H\u00e9matologie"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:20:08Z","timestamp":1762104008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121002800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":7,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0007455121002800"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.07.002","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DESCAR-T, le registre national des patients trait\u00e9s par CAR-T Cells","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}